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Harmonising data collection from osteoarthritis
studies to enable stratification: recommendations on
core data collection from an Arthritis Research UK
clinical studies group
Sarah R. Kingsbury1, Nadia Corp2, Fiona E. Watt3, David T. Felson4,5, Terence
W. O’Neill4, Cathy A. Holt6, Richard K. Jones7, Philip G. Conaghan1, Arthritis
Research UK Osteoarthritis and Crystal Disease Clinical Studies Group working
group* and Nigel K. Arden8,9
Abstract
Objective. Treatment of OA by stratifying for commonly used and novel therapies will likely improve the
range of effective therapy options and their rational deployment in this undertreated, chronic disease. In
order to develop appropriate datasets for conducting post hoc analyses to inform approaches to strati-
fication for OA, our aim was to develop recommendations on the minimum data that should be recorded
at baseline in all future OA interventional and observational studies.
Methods. An Arthritis Research UK study group comprised of 32 experts used a Delphi-style approach
supported by a literature review of systematic reviews to come to a consensus on core data collection for
OA studies.
Results. Thirty-five systematic reviews were used as the basis for the consensus group discussion. For
studies with a primary structural endpoint, core domains for collection were defined as BMI, age, gender,
racial origin, comorbidities, baseline OA pain, pain in other joints and occupation. In addition to the items
generalizable to all anatomical sites, joint-specific domains included radiographic measures, surgical his-
tory and anatomical factors, including alignment. To demonstrate clinical relevance for symptom studies,
the collection of mental health score, self-efficacy and depression scales were advised in addition to the
above.
Conclusions. Currently it is not possible to stratify patients with OA into therapeutic groups. A list of core
and optional data to be collected in all OA interventional and observational studies was developed,
providing a basis for future analyses to identify predictors of progression or response to treatment.
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Rheumatology key messages
. Stratification of therapy is key to improving OA treatment.
. Development of OA stratification criteria requires harmonized data collection to enable analysis of pooled data.
. We developed a set of core and optional components for data collection across all OA studies.
Introduction
OA represents a considerable worldwide health and eco-
nomic challenge [1]. Although OA is a heterogeneous dis-
ease driven by a variety of pathophysiologic factors,
current therapy selection is largely arbitrary. In general,
treatment is aimed at symptomatic relief rather than tar-
geting pathology, and the choice of therapeutic agent is
often based on potential toxicity without consideration of
likely efficacy. As such, efficacy of these currently avail-
able treatments is poor in the majority of people with OA
[2]. Stratification of patients towards targeting of com-
monly used as well as novel therapies will likely improve
the range of effective treatment options and their rational
deployment in this undertreated chronic disease.
The development of a stratification strategy for OA re-
quires knowledge of both predictors of disease progres-
sion to identify patients requiring treatment and predictors
of the response to treatment, which together will allow the
identification of subsets of patients within which treat-
ments may have improved efficacy. Such data may be
gathered prospectively in well-designed interventional
and observational studies and retrospectively through
post hoc analyses of single studies and linking or pooling
of study data for meta-analyses. To ensure robust ana-
lyses and reliability of results, consistent data collection
across studies is essential.
In order to develop appropriate datasets for stratifica-
tion in OA, our aim was to develop advice on what min-
imum data should be recorded at baseline in all future OA
interventional and observational studies.
Methods
The Arthritis Research UK Osteoarthritis and Crystal
Diseases Clinical Studies Group conducted a literature
review of systematic reviews and convened an expert
consensus group to consider core data collection to
allow post hoc stratification analyses to be conducted.
Literature review
A review of systematic reviews was conducted to identify
prognostic factors of OA in general and more specifically
for knee, hip and hand OA. Systematic searches were
conducted across four electronic databases [Cochrane
Library, Embase (OVID), Medline (OVID) and Web of
Science] from inception to August 2015. The search strat-
egy (supplementary Table S1, available at Rheumatology
Online) was designed in OVID Medline using text words
and MeSH and combining terms for OA, prognosis and
systematic review. For the other databases, search terms
were adapted to the search capabilities of the database.
Non-English-language articles, letters, comments and
editorials were excluded. Evidence was graded according
to classifications in the included reviews, which were
designated as conflicting, weak/limited, moderate and
strong.
Consensus group discussion
A group of 32 stakeholders, including rheumatologists,
physiotherapists, podiatrists, trialists, orthopaedic sur-
geons, primary care physicians, scientists and patient
representatives who have a particular interest in OA, at-
tended a meeting where the findings of the literature
review were presented. The panel meeting started with a
predefined objective presented by the chair (P.C.). The
objective was to develop guidelines to harmonize data
collection across all OA clinical studies.
After discussion, it was agreed that development of rec-
ommendations for studies should be based on the prede-
termined principles explained here. Only clinically relevant
domains should be included in the core list. These may be
different for trials with structural or symptomatic end-
points. Domains would be based on existing recommen-
dations for appropriate domains to be assessed (including
those from the OMERACT).
For the data item to be recommended as a core com-
ponent there should be evidence of either predicting re-
sponse to treatment or as a risk factor for progression of
OA. Where insufficient evidence currently exists, items
should not be included in core components, but may be
recommended as additional information to be captured at
the study team’s discretion. Since an extensive literature
review on the tools used to capture each component was
not conducted, the use of a set tool would not be recom-
mended. However, potential tools or mechanisms used to
capture each component would be suggested. The choice
of tool should depend on its extent of validation and psy-
chometric robustness as well as feasibility issues, includ-
ing costs. The core components should be revised as
more data become available, with a maximum of 5 years
before the next revision. Items may be generalizable to all
anatomical sites of OA or specific to a particular joint. In
trials designed with a primary structural endpoint, symp-
tomatic domains should also be measured to assess the
clinical relevance of structural change. Recommendations
should apply to all types of OA clinical studies, including
pharmacological and non-pharmacological interventional
trials and observational studies.
The literature summarizing the current evidence for
prognostic factors for OA was presented (N.C.). The
panel was then prompted to identify the domains that
were felt to be important for inclusion in the core data
items and these were compiled. Once identified, each
domain was discussed and considered in line with the
presented evidence to determine whether they fulfilled
the criteria for core data, and those with insufficient
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evidence were excluded at this time. The discussion was
separated by joint, with separate consideration of data
collection for knee, hip and hand studies. Consensus on
inclusion/exclusion of domains was defined where there
was 100% verbal agreement from the panel. For each
domain included, appropriate tools for assessment were
discussed. Domains for which there was a consensus
were included in a list of provisional domains. The provi-
sional list was then transcribed and circulated 1 week
after the consensus meeting. This was then refined and
finalized following an iterative electronic discussion invol-
ving the entire panel.
Results
Literature review
A total of 35 systematic reviews were identified for inclu-
sion. Thirteen reported on factors associated with struc-
tural/radiographic OA progression, 10 on functional/
symptom progression and a further 15 on factors affecting
outcomes of interventions for or associated with OA. These
were categorized according to the location of OA, type of
progression reported, level of evidence identified by the
systematic review and whether an association was found
or not.
Literature on structural progression
Knee OA
Eight systematic reviews reported on structural/radio-
graphic progression of knee OA (Table 1) [310]. Two
also reported on clinical outcomes and are therefore also
included with respect to symptom progression. Strong evi-
dence was found for significant associations of the follow-
ing factors with structural progression: increasing age [3];
presence of generalized/multijoint OA [3, 4]; combined
radiographic features including increasing osteophyte
score, joint space width (JSW), joint space narrowing
(JSN), KellgrenLawrence (KL) grade and chondrocalcino-
sis [3]; varus alignment [3, 6, 10]; baseline pain [10]; anterior
cruciate ligament injury [8]; increasing serum hyaluronic
acid [4, 10]; high levels of TNF-a [10] and increasing urinary
C-telopeptide of type II collagen (uCTX-II) [7]. Strong evi-
dence of no significant association was found for physical/
regular sports activity or moderate exercise [35], radio-
logical severity at baseline [4], baseline pain [4], quadriceps
strength [4] and knee injury [4]. Conflicting evidence was
reported for association of BMI, clinical/disease severity,
leg length inequality and symptom duration with radiologic
progression [3, 4].
Hip OA
Three systematic reviews examined the progression of hip
OA; progression was based on radiological parameters
and/or the need for total hip replacement with no clear
differentiation made (Table 1) [7, 11, 12]. Strong evidence
was found for significant associations of the following fac-
tors with structural and/or symptomatic progression:
increasing age [11], radiological grade KL hip grade 3
[11], clinical/disease severity (Lequesne index score510)
[11], smaller JSW at baseline [11], supero-lateral femoral
head migration [11, 12], presence of femoral osteophytes
only [11], presence of bony sclerosis [11], atrophic bone
response [12] and higher baseline hip pain [11]. Strong
evidence for no association was found for the following
factors: BMI and weight [12] and acetabular osteophytes
[11]. Conflicting or limited evidence was reported for as-
sociation with gender, JSN and uCTX-II with structural
progression [7, 12].
Hand OA
One systematic review reported on structural/radio-
graphic progression of hand OA [13]. No strong evidence
was available for any factors with a relationship to pro-
gression. Limited evidence for association of baseline
pain, early menopause, nodal OA and erosive OA with
radiographic progression was reported [13].
General OA
Two systematic reviews reported on structural/radio-
graphic progression of general OA (either hip OA or
knee OA or both hip and knee OA), neither of which iden-
tified strong evidence for any factors related to progres-
sion [14, 15].
Literature on symptom progression
Knee OA
Five systematic reviews reported on functional/symptomatic
progression of knee OA (Table 1) [3, 5, 1618]. Strong evi-
dence was indicated for the association of the following
factors with progression? increasing age [3]; presence of
generalized/multijoint OA [3]; combined radiographic fea-
tures including increasing osteophyte score, JSW, JSN,
KL grade and chondrocalcinosis [3]; and varus alignment
[3]. Physical activity was not associated with progression
[3]. There was conflicting or limited evidence for associ-
ations with BMI [3, 17, 18], gender [3, 17, 18], symptom
severity [3, 17, 18], mental health score [3, 17, 18], self-
efficacy [3, 16, 17], clinical/disease severity [3], co-morbidity
[17, 18] and baseline pain [3] with symptomatic progression.
Hip OA
There were no systematic reviews that reported on func-
tional/symptomatic progression of hip OA.
Hand OA
Two systematic reviews reported on functional/symptom-
atic progression of hand OA [13, 19]. Kwok et al. [13] found
no strong evidence available for the relationship of any fac-
tors to progression, while Nicholls et al. [19] concluded no
information was available on the progression of hand pain
and function over time. Limited evidence was reported for
an association of age, baseline pain, number of painful
joints and function with symptomatic progression, while
limited evidence for no association with symptomatic pro-
gression was reported for nodal and erosive OA [13].
General OA
Three systematic reviews reported on functional/symp-
tomatic progression of general OA (hip OA, knee OA or
1396 www.rheumatology.oxfordjournals.org
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both) [20], chronic musculoskeletal disease [21] and
chronic disorders [22]. Strong evidence was indicated
for lower self-efficacy as a predictor of disability in general
OA [20]. However self-efficacy was not associated with
pain in general OA [20].
Literature on response to interventions
Knee OA
Eleven systematic reviews reported on factors affecting
outcomes of interventions for or including knee OA
(Table 2) [2333]. Strong evidence was indicated for as-
sociation of the following factors with symptomatic out-
comes? female gender was associated with pain while
waiting for total joint replacement [28], worse preoperative
mental health score was associated with lower function
and greater pain >1 year after total knee arthroplasty
(TKA) [25], increased pain catastrophizing was associated
with postoperative pain within 1 year after TKA [25],
postoperative self-efficacy was associated with short-
and long-term outcomes [32] and co-morbidity was asso-
ciated with TKA outcomes [30]. The following factors were
found not to be associated with symptomatic outcomes?
preoperative depression and anxiety was not associated
with postoperative functioning within 1 year after TKA [25]
and wait for surgery (<180 days) was not associated with
pain progression [28]. Limited or conflicting evidence was
reported for association of age, BMI, baseline pain and
pain duration with response to intra-articular steroid injec-
tion [23] and for association of BMI, age and health-
related quality of life with TKA outcomes [29, 30, 33].
Hip OA
Nine systematic reviews reported on factors affecting out-
comes of interventions for or including hip OA (Table 2)
TABLE 1 Summary of the literature on structural and symptomatic progression
Knee OA
Hip OA
Domain
Structural/radiographic
progression
Functional/symptomatic
progression
Structural/radiographic
progression
Age Predictivea [3] Predictivea [3] Predictive [11]
Gender No association [4] — —
BMI or weight — No association [12]
Physical activity/regular sports
activity
No association [3, 4] No association [3] —
Baseline pain No association [4];
Predictive [10]
— Predictive [11]
Clinical/disease severity
(Lequesne index score 510)
Predictive [11]
Generalized/multiple joint OA Predictivea [3];
Association [4]
Predictivea [3] —
Combined radiographic fea-
tures including osteophyte
score, JSW, JSN, KL grade,
chondrocalcinosis
Predictivea [3] Predictivea [3] —
Radiological grade (KL grade 3) — — Predictive [11]
Baseline radiological severity No association [4] — —
JSW at baseline — — Predictive [11]
Femoral head migration — — Predictive [11];
Association [12]
Femoral osteophytes — — Predictive [11]
Acetabular osteophytes — — No association [11]
Bony sclerosis — — Predictive [11]
Heberdon’s nodes Predictive [10]
Atrophic bone response —- — Association [12]
Alignment (varus/valgus) Predictivea
(varus alignment) [3] [10];
association [6]
Predictivea
(varus alignment) [3]
—
Quadriceps muscle strength No association [4] — —
Knee injury No association [4] — —
Anterior cruciate ligament injury Association [8]
Serum hyaluronic acid Association [4];
Predictive [10]
— —
TNF-a Predictive [10]
uCTX-II Association [7]
aProgression defined as change in pain, function or deterioration in radiographic features. Factors reported in systematic
reviews as having a strong level of evidence for an association or no association with structural or symptomatic progression of
knee and hip OA.
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[12, 23, 2730, 32, 34, 35]. Strong evidence was found for
an association of female gender with pain while waiting for
total joint replacement [28]. Co-morbidity was associated
with total hip arthroplasty (THA) outcomes [30]. No asso-
ciation was found between wait for surgery (<180 days)
and progression of pain or self-reported functioning [28].
Limited evidence was reported for association of age and
health-related quality of life with THA outcomes and with
response to intra-articular steroid injection [23, 29, 30].
Consensus group recommendation on structural
progression
The recommended core items for inclusion in structural
progression studies are outlined in Table 3. Injury is
known to be an important risk factor for the onset of
OA, but its role in progression is less clear and it was
therefore not included in the core list. While collection of
biological samples is highly desirable, especially for novel
biomarker development, with only uCTX-II, serum hyalur-
onic acid and TNF-a showing evidence of association, it
was agreed that their inclusion as a core item could not be
justified based on current evidence. However, where
study design and logistics allow, collection of biological
samples is encouraged. The following items were not
agreed for inclusion in the core components at this time
due to insufficient evidence: clinical measures of inflam-
mation, structural response to loading, joint circumfer-
ence, joint laxity, patient-reported aetiology and patient
expectation. Although there was conflicting evidence for
an association of structural progression with BMI, includ-
ing strong evidence for no association with hip OA, it was
agreed that this should be included in the core data. Co-
morbidity was not examined within any of the structural
progression reviews, however, given the reported associ-
ation of co-morbidity with THA and TKA outcomes and its
association with symptom outcomes, it was agreed that
this should be collected within the core items. Advice for
hand OA was confounded by there being only a single
systematic review that identified no strong associations
with structural progression. On discussion it was agreed
that hand surgery, hand dominance and menopausal age
should be collected to inform future analyses.
Consensus group recommendation on symptom
progression
It was agreed that all of the core items recommended for
structural progression should be included in the core list for
symptom progression. The following additional core items
were proposed to be included in symptom progression
studies to ensure demonstration of clinical relevance:
mental health score, self-efficacy and depression or anxiety
(Table 3). The difference between the severity of symptoms
and symptom progression was noted. In longitudinal co-
horts, symptoms have been found to remain stable over
years in many patients with knee OA, although different
patterns of symptoms have been described [36, 37].
Further consideration is therefore required to define symp-
tom progression, for example, how to define a patient with
worse pain and unchanged X-ray compared with a patient
with X-ray progression and unchanged pain.
Advice on choice of tools for data collection
While these recommendations did not set out to recom-
mend a set tool to capture each domain, to ensure con-
sistency in data collection and thus improve the
opportunity for data to be pooled, it is suggested that,
TABLE 2 Summary of literature on response to interventions
Domain
Intervention
outcomes (knee OA)
Intervention
outcomes (hip OA)
Intervention
outcomes (OA general)a
Gender Association with pain while
waiting for TJA [28]
Association with pain while
waiting for TJA [28]
Association with pain
while waiting for TJA [28]
Physical activity/regular
sports activity
— —
Wait for TJA surgery
<180 days
No association with
pain progression [28]
No association with
pain progression [28]
—
Mental health score Association with lower
function and pain 51 year
post TKA [25]
— —
Preoperative depression No association with
postoperative functioning
<1 year post-TKA [25]
— —
Depression — —
Pain catastrophizing Association with postoperative
pain, <1 year post-TKA [25]
—
Self-efficacy — — Post-TJA self-efficacy
associated with short and
long-term outcomes [32]
Co-morbidity Associated with outcomes [30] Associated with
outcomes [30]
aDefined as hip OA, knee OA or both. Factors reported in systematic reviews as having a strong level of evidence for an
association or no association with knee and hip and general OA intervention outcomes.
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where possible, items are captured using validated tools
and with reference to other clinical studies that might pro-
vide an opportunity for later data pooling. Within the scope
of these recommendations, we have therefore provided
guidance on potential tools that may be considered
during study design, but this does not represent a definitive
list. For capturing multisite joint pain, use of a joint pain
manikin is suggested, since joint counts do not reflect the
distribution of joints. At a minimum, such a manikin should
capture the joint region (e.g. hand, foot, ankle), although at
the discretion of the investigator further differentiation may
be captured (e.g. ball of the foot, mid-foot, hindfoot). In line
with current IMMPACT guidelines, an 11-point numerical
rating scale with a 1-week recall period is suggested for
capturing baseline pain [38]. Other validated questionnaires
may also be considered for assessing pain and function,
including but not limited to joint-specific scales such as the
Knee Injury and Osteoarthritis Outcomes Score, Hip Injury
and Osteoarthritis Outcomes Score, WOMAC, Oxford
Knee/Hip Score, Australian/Canadian Osteoarthritis Hand
Index and Functional Index for Hand Osteoarthritis
[3943]. It is recommended that alignment should be cap-
tured at a minimum using a measure of varus/valgus de-
formity, but where possible, consideration should be made
for inclusion of either a weight-bearing long leg X-ray,
which would indicate static alignment in the sagittal
plane, or gait assessment, to indicate coronal and sagittal
plane hipkneeankle angles and tibial rotation and, if pos-
sible, a measure of anteriorposterior deceleration/acceler-
ation of the centre of mass [44]. Where imaging outcomes
are included in studies, X-rays should be captured using
published protocols to ensure consistency and a weight-
bearing (where appropriate) KL grade assessed as a
minimum [45, 46]. It is suggested that physical activity be
captured using an accelerometer or combined gyroscopic-
based measures where possible. Alternatively, a simple
performance-based test, such as the 30 s chair stand
test, the 4  10 m fast walk test and/or the timed stair
test [47], or a patient-reported outcome (PRO) may be con-
sidered. Potential PROs include the Physical Activity Scale
in the Elderly, International Physical Activity Questionnaire
or Tegner Activity Scale, or a simple question that captures
sedentary versus active lifestyle [48, 49].
Discussion
For researchers undertaking clinical studies, these recom-
mendations provide an important resource to underpin
study design. Furthermore, as new studies are developed
in line with these recommendations, a valuable resource
will be established to inform future post hoc analyses of
data pooled from multiple studies. Such analyses may
include examining predictors of disease progression to
identify patients requiring treatment and predictors of
the response to treatment, informing the subsetting of pa-
tients within which treatments may have improved
efficacy.
The distinction between the recommendations described
herein and the work by OMERACT to develop core out-
come sets for rheumatologic conditions must be noted.
The aim of the OMERACT process is to develop core
sets that specify, for each condition, the areas/domains
(and associated measurement instruments) necessary to
provide the best estimate of benefits of an intervention
within the context of a clinical trial or observational study
[50]. In contrast, the aim of the current recommendations is
to harmonize data collection in order to enable pooling of
data (using domains derived from the existing literature,
which were influenced by the OMERACT OA core set) for
future meta-analyses to examine predictors of response to
an intervention and to identify patient phenotypes for stra-
tified therapy. As such, we recommend that these compo-
nents should be collected at baseline as a minimum, to
enable definition of patient subgroups in future analyses,
with inclusion in additional study visits at the discretion of
the investigators and considered with respect to staff and
subject time, expense and applicability to the study in
question.
The consensus meeting identified a current relative
paucity of data to allow stratification of patients with OA
into therapeutic groups, highlighting the need for these
recommendations in order to provide a foundation to
enable stratified OA treatment. Part of the problem lies
in the lack of standardisation of the data collected in clin-
ical trials, with resultant limited ability to pool data from
different trials to identify predictors of progression or of
response to treatment. The harmonization of data
TABLE 3 Recommended core data collection for OA studies
Structural studies Essential Desirable
General (all site) BMI, age, gender, racial origin, comorbidity, baseline OA pain, pain
in other joints, occupation
Physical activity
Knee specific X-ray grade of target joint (weight-bearing KL as minimum) + osteophytes
and chondrocalcinosis, previous knee surgery including arthroscopy,
alignment (varus/valgus), weight-bearing long leg X-ray or gait assessment
Hip specific X-ray grade of target joint + osteophytes and chondrocalcinosis,
morphology (head, ball and socket), previous hip surgery, history of FAI
Leg length
discrepancy
Hand specific X-ray grade of target joint + osteophytes and chondrocalcinosis,
previous hand surgery, hand dominance, age at menopause
Additional data collection for symptom studies
General (all site) Mental health score, self-efficacy, depression or anxiety
FAI: femoro-acetabular impingement.
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collected as recommended herein will allow these issues
to be addressed and enable the treatment of OA to move
into the era of personalized medicine. The consensus pro-
cess identified a number of core components for which
there is already some evidence of association with the
progression of OA, either at a structural or a symptomatic
level. Collection of these components, at baseline as a
minimum, provides the starting point for efforts to develop
stratification algorithms for OA treatment.
While the current evidence has suggested a number of
factors that are not associated with structural and/or
symptomatic progression, this does not preclude their in-
clusion within a study. For example, while injury is known
to be an important risk factor for the onset of OA, current
evidence suggests that there is no relationship between
knee injury and structural progression. However, analyses
of association with progression are limited by the use of
multiple mechanisms of assessment, and standardisation
of individual tools or assessments used may reveal further
elements associated with symptom or structural progres-
sion for inclusion. Furthermore, the assessment of asso-
ciation of injury with OA progression did not consider
factors such as measurement of ongoing joint instability
or accurate subanalysis of the type of injury, which may
mediate the effect of any such association. Further meas-
ures that may be considered include patient-reported
measures such as quality of life, serum and urine bio-
markers and imaging biomarkers, including US and MRI.
Although the latter were not examined within any of the
reviews examined herein, with current efforts to develop
disease-modifying OA drugs, including agents targeted at
specific OA pathologies such as synovitis and bone
marrow lesions, such data may prove highly valuable in
determining patient phenotypes for individual therapies.
Selection of additional components should remain at the
discretion of the investigator and reflect appropriateness
to the study in question as well as resource issues and
patient burden. With inclusion of such components in stu-
dies, new evidence will enable further refinement of these
recommendations and result in the addition of further
domains to the core components.
There are a number of limitations to this work. The sys-
tematic literature review only included relevant systematic
reviews and meta-analyses relating to the symptomatic
and/or structural progression of OA and did not review
primary papers or studies examining risk factors for the
onset of OA. The dissemination plan was limited to pres-
entation at national meetings and journal publication. The
recommendations have not been piloted among users;
however, there is a mechanism for updating the recom-
mendations within the Clinical Studies Group framework.
Finally, since we were unable to recommend a specific
tool for each component, an element of variability will
remain among studies designed according to these guide-
lines. Future work may seek to extend these recommen-
dations with a robust review of the potential tools that may
be used to assess each data component so as to improve
uniformity further. We are aware of an ongoing EULAR
project to detail the available psychometric properties of
the commonly used OA outcome measures. Despite these
limitations, we believe the work is strengthened by the
breadth of stakeholders involved in the consensus pro-
cess, and most importantly, inclusion of patient and
public representation.
In summary, we recommend that in the design of new
clinical studies, both interventional and observational, the
data components to be captured should be carefully con-
sidered in light of these recommendations. Furthermore,
care should be taken to include validated tools for all com-
ponents, and where possible, to consider the design of
similar studies that may provide the opportunity for future
data pooling. Through considered, informed and unified
study design we have the potential to provide a powerful
substrate for future studies to underpin stratified treatment
for OA. Such stratification of patients with OA may involve
the use of clinical criteria, biomarkers or functional markers
to target a treatment to a patient that is likely to progress
with a phenotype that is driven by the pathway targeted by
the treatment under investigation. Novel biomarkers may
enable better application of a current treatment or the
emergence of a new biomarker/treatment combination
that would simultaneously develop a method of stratifica-
tion and a new treatment. As new biomarkers become
available, inclusion in the recommended core data will
need to be considered.
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